Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Shorted: Short Interest Up 86.7% in September

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 59,859 shares, a growth of 86.7% from the August 31st total of 32,056 shares. Based on an average daily volume of 159,917 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.0% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on FSNUY. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy”.

Fresenius SE & Co. Price Performance

Shares of FSNUY stock traded down $0.93 during trading on Tuesday, hitting $12.42. The company had a trading volume of 7,321 shares, compared to its average volume of 145,590. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market capitalization of $27.98 billion, a P/E ratio of 15.72 and a beta of 0.62. The stock’s 50-day moving average price is $13.18 and its 200 day moving average price is $12.42. Fresenius SE & Co. has a one year low of $10.33 and a one year high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%.The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Equities analysts expect that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.